Senator Bernie Sanders wrote a letter urging Novo Nordisk to lower prices for its diabetes and weight loss drugs in the U.S. However, Denmark, where the company is based, was also facing challenges with the high costs of the drugs. Other countries negotiate lower prices for the same drugs, leading to budget constraints in healthcare systems. The high prices also impact patients’ access to the drugs, with insurance coverage and availability fluctuating. There is ongoing debate over coverage for weight loss drugs, and the potential impact on federal and commercial insurance budgets is uncertain. Novo Nordisk’s lobbying efforts and the future of Medicare price negotiations for the drugs are subjects of concern.
Source link
How Little Denmark Got Homegrown Giant Novo Nordisk To Lower Ozempic Prices
